Top Markets
Coin of the day
Reviva Pharmaceuticals Holdings, Inc. Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc.

RVPHW
Rang in aandelen #39800
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical... Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for diseases with substantial unmet medical needs. Their pipeline targets disorders within the central nervous system, respiratory, cardiovascular, metabolic, and inflammatory disease categories. The company's leading drug candidate, brilaroxazine (RP5063), is currently in Phase III clinical trials for the treatment of schizophrenia. This compound has also completed Phase I trials for a diverse set of conditions, including bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, the behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Furthermore, Reviva is advancing RP1208, which is in pre-clinical development for depression and obesity. Founded in 2018, the company is headquartered in Cupertino, California.
Aandeelprijs
$0.003
Laatst gesynchroniseerd: 2025-12-12
Marktkapitalisatie
$343.91K
Verandering (1 dag)
-16.67%
Verandering (1 jaar)
-90.23%
Land
US
Handel Reviva Pharmaceuticals Holdings, Inc. (RVPHW)

Categorie

EPS voor Reviva Pharmaceuticals Holdings, Inc. (RVPHW)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Reviva Pharmaceuticals Holdings, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Reviva Pharmaceuticals Holdings, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten